Newsletter

214450 - Pharma Research Co., Ltd.

214450 Summary
Medical Devices
Stock Price & Overview
₩386,500 +5,500 (+1.44%) Close · Sep 4, 2026 KST
KOSDAQ | ₩KRW | Close: ₩386,500  ≈ US$276  ·  Market cap ₩4.0tn (≈ $2.9bn)

214450 Quarterly Results

Quarter ₩bnRevenueYoYOperating incomeMarginYoYNet incomeEPS
2026 Q2178.7+27.1%66.537.2%+19.0%56.2₩5,412
2026 Q1146.1+25.0%57.339.2%+28.1%48.7₩4,692
2025 Q4143.3+39.1%51.936.2%+54.1%39.3₩3,786
2025 Q3135.4+51.8%61.945.7%+77.2%50.9₩4,895
2025 Q2140.6+69.2%55.939.7%+81.7%42.0₩4,047
2025 Q1116.9+56.5%44.738.3%+67.7%36.0₩3,468
2024 Q4103.1—33.732.7%—16.4₩1,579
2024 Q389.2—34.939.1%—25.5₩2,456
Three-month figures from DART consolidated statements. Q4 is the annual figure less the nine-month cumulative. EPS is net income over today's share count, so buybacks and issuance move earlier quarters. YoY compares with the same quarter a year earlier and is blank when that quarter was a loss.

214450 Annual Results

Full statements »
Fiscal year ₩bnRevenueYoYOperating incomeMarginYoYNet incomeEPS
FY2025536.3+53.2%214.440.0%+70.1%168.3₩16,195
FY2024350.1+34.1%126.136.0%+36.6%88.9₩8,561
FY2023261.0+34.0%92.335.3%+40.0%77.3₩7,437
FY2022194.8+26.4%65.933.8%+25.6%43.4₩4,181
FY2021154.1+41.7%52.534.1%+57.0%46.8₩4,507
FY2020108.7+29.7%33.430.7%+75.4%32.5₩3,124

214450 Next Report

The latest quarter on file is 2026 Q2. The next one, the Q3 2026 report covering the period to Sep 30, 2026, is due on DART by Nov 14, 2026 — Korean issuers must file quarterly and half-year reports within 45 days of period end and the annual report within 90 days.

Large issuers usually publish preliminary consolidated figures (잠정실적, a fair-disclosure filing with revenue and operating profit only) in the first weeks after the period ends, ahead of the full report. kstock does not know a company's chosen release date; when the preliminary filing arrives it appears under Filings and on this page.

214450 Earnings Filings

All filings »
DART

Half-Year Report

Periodic08/14/26title translated
DART

Preliminary Consolidated Results (Fair Disclosure)

Earnings08/07/26title translated
DART

Quarterly Report

Periodic05/15/26title translated
DART

Preliminary Consolidated Results (Fair Disclosure)

Earnings05/08/26title translated

How Korean earnings differ from US earnings

  • No quarterly guidance culture. Most KRX companies give no EPS or revenue guidance; the preliminary filing is the first number the market sees, and there is no consensus beat/miss ritual built around it.
  • Preliminary first, then the report. The 잠정실적 filing carries revenue and operating profit; net income and the balance sheet come with the full report weeks later.
  • Consolidated is the headline. Korean companies report consolidated (K-IFRS) and separate (parent-only) figures; kstock uses consolidated unless the page says otherwise.
  • Fiscal years end in December for almost every listed company, so Q4 is derived: the annual figure less the nine-month cumulative.

Similar to 214450

SymbolLast Price
214150Classys, Inc.₩31,800
+0.3%
096530Seegene, Inc.₩31,900
+1.1%
491000Livs Med, Inc.₩34,500
+3.6%
041830In Body Co., Ltd.₩61,100
+2.5%
445680Curiox Biosystems Co., Ltd.₩47,650
-1.5%
458870Seers Co., Ltd.₩21,350
+3.1%
137310SD Biosensor₩6,160
-0.3%
377740Bio Note, Inc.₩4,790
-0.2%
340570T & L Co., Ltd.₩29,650
+1.2%
099190i-SENS, Inc.₩16,470
+0.0%
Compare all 13 in Medical Devices

What a US investor should know

  • Trading hours09:00–15:30 KST — 20:00–02:30 US Eastern the night before.
  • Daily limitKorean stocks can move at most ±30% in a session before trading halts.
  • Getting exposureKRX shares are not directly tradable in most US brokerage accounts. The usual routes are Korea ETFs or an international account.
  • ReportingKorean issuers file to DART, not the SEC. Half-year and quarterly reports land about 45 days after period end.